Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery. Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses. Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response. Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC. Drs. Posadas and Ambinder reflect on the first AUA guideline update for salvage therapy in prostate cancer in over a decade. Dr. Marc Dall'Era spotlights the results from a phase 2 trial on neoadjuvant niraparib for DDR-deficient localized PCa. Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy. Dr. John Gore offers interesting data from the CISTO study, favoring radical cystectomy for recurrent high-grade NMIBC. Dr. Joseph Jacob shares the latest 1-year durability and PROs related to TAR-200 for BCG-unresponsive high-risk NMIBC. Dr. Jayram highlights the updates in the ADVANCED-2 study: TARA-002 for patients with high-grade NMIBC. Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge. Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro. Dr. Yerram elucidates the evolving landscape of focal therapy for prostate cancer, emphasizing its ease of adoption. Dr. Yerram describes his post-HIFU surveillance protocol: regular PSA checks, MRI, and biopsies at defined intervals. Dr. Yerram explains the use of HIFU and cryotherapy as primary focal therapy modalities, emphasizing a few treatment options. Dr. Yerram explains how advances in focal therapy technologies over the past decade have driven increased use and acceptance. Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease. Dr. Hong reviews the criteria used to determine which patients may benefit from MDT. Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision. CA9 imaging and ZIRCON data offer new insight into managing small renal masses and supporting personalized kidney cancer care